Aduhelm reignites ques­tions around ties be­tween phar­ma and pa­tient ad­vo­ca­cy orgs

In the lat­est round of pa­tient ad­vo­ca­cy and the FDA, the drug re­view­er ap­proved Bio­gen and Ei­sai’s Alzheimer’s dis­ease med Aduhelm over the ad­vice of its own ad­comm. Crit­ics point­ed to pres­sure from phar­ma-fund­ed ad­vo­ca­cy groups such as the Alzheimer’s As­so­ci­a­tion and its so­cial me­dia cam­paigns as de­cid­ing fac­tors. How­ev­er, the As­so­ci­a­tion and oth­er groups who spoke up for a treat­ment main­tain that they’re neu­tral and fo­cus on pa­tients’ needs and the need for treat­ment in the dev­as­tat­ing dis­ease.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.